Servier cuts off collaboration agreement with Allogene on CD19 products, sending shares sputtering

Allogene Therapeutics said in an SEC filing today that French partner Servier has cut off its involvement in a partnership developing therapies directed against CD19, including the most advanced candidates in Allogene’s pipeline.

Shares of Allogene $ALLO, an...

Click to view original post